We have located links that may give you full text access.
Clinical Trial
Journal Article
Detection of HER2 expression using 99m Tc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial.
Breast Cancer Research : BCR 2024 March 9
BACKGROUND: 99m Tc radiolabeled nanobody NM-02 (99m Tc-NM-02) is a novel single photon emission computed tomography (SPECT) probe with a high affinity and specificity for human epidermal growth factor receptor 2 (HER2). In this study, a clinical imaging trial was conducted to investigate the relationship between 99m Tc-NM-02 uptake and HER2 expression in patients with breast cancer.
METHODS: Thirty patients with pathologically confirmed breast cancer were recruited and imaged with both 99m Tc-NM-02 SPECT/computed tomography (CT) and 18 F-fluorodeoxyglucose (18 F-FDG) positron emission tomography (PET)/CT. According to the treatment conditions before recruitment, patients were divided into two groups, the newly diagnosed group (n = 24) and the treated group (n = 6). The maximal standard uptake value (SUVmax ) of 18 F-FDG and SUVmax and mean SUV (SUVmean ) of 99m Tc-NM-02 in the lesions were determined to analyze the relationship with HER2 expression.
RESULTS: No meaningful relationship was observed between 18 F-FDG uptake and HER2 expression in 30 patients with breast cancer. 99m Tc-NM-02 uptake was positively correlated with HER2 expression in the newly diagnosed group, but no correlation was observed in the treated group. 99m Tc-NM-02 uptake in HER2-positive lesions was lower in those with effective HER2-targeted therapy compared with the newly diagnosed group. 99m Tc-NM-02 SPECT/CT detected brain and bone metastases of breast cancer with a different imaging pattern from 18 F-FDG PET/CT. 99m Tc-NM-02 showed no non-specific uptake in inflamed tissues and revealed intra- and intertumoral HER2 heterogeneity by SPECT/CT imaging in 9 of the 30 patients with breast cancer.
CONCLUSIONS: 99m Tc-NM-02 SPECT/CT has the potential for visualizing whole-body HER2 overexpression in untreated patients, making it a promising method for HER2 assessment in patients with breast cancer.
TRIAL REGISTRATION: NCT04674722, Date of registration: December 19, 2020.
METHODS: Thirty patients with pathologically confirmed breast cancer were recruited and imaged with both 99m Tc-NM-02 SPECT/computed tomography (CT) and 18 F-fluorodeoxyglucose (18 F-FDG) positron emission tomography (PET)/CT. According to the treatment conditions before recruitment, patients were divided into two groups, the newly diagnosed group (n = 24) and the treated group (n = 6). The maximal standard uptake value (SUVmax ) of 18 F-FDG and SUVmax and mean SUV (SUVmean ) of 99m Tc-NM-02 in the lesions were determined to analyze the relationship with HER2 expression.
RESULTS: No meaningful relationship was observed between 18 F-FDG uptake and HER2 expression in 30 patients with breast cancer. 99m Tc-NM-02 uptake was positively correlated with HER2 expression in the newly diagnosed group, but no correlation was observed in the treated group. 99m Tc-NM-02 uptake in HER2-positive lesions was lower in those with effective HER2-targeted therapy compared with the newly diagnosed group. 99m Tc-NM-02 SPECT/CT detected brain and bone metastases of breast cancer with a different imaging pattern from 18 F-FDG PET/CT. 99m Tc-NM-02 showed no non-specific uptake in inflamed tissues and revealed intra- and intertumoral HER2 heterogeneity by SPECT/CT imaging in 9 of the 30 patients with breast cancer.
CONCLUSIONS: 99m Tc-NM-02 SPECT/CT has the potential for visualizing whole-body HER2 overexpression in untreated patients, making it a promising method for HER2 assessment in patients with breast cancer.
TRIAL REGISTRATION: NCT04674722, Date of registration: December 19, 2020.
Full text links
Related Resources
Trending Papers
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app